GlobeStar Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to the development of messenger RNA (mRNA)-based therapies for serious diseases. The company’s core focus lies in leveraging proprietary lipid nanoparticle delivery systems to transport mRNA payloads to target cells, enabling the expression of therapeutic proteins that address underlying disease mechanisms. GlobeStar’s research and development efforts encompass both oncology and rare genetic disorders, with multiple preclinical programs advancing toward Investigational New Drug (IND) applications with the U.S. Food and Drug Administration (FDA).
At the heart of GlobeStar’s platform is an exclusive licensing agreement for LUNAR™ lipid nanoparticle technology, which has been optimized to enhance intracellular delivery and minimize off-target effects. The company’s lead oncology candidate encodes interleukin-12 for localized immunotherapy in solid tumors, aiming to recruit and activate antitumor immune cells within the tumor microenvironment. In parallel, a second program focuses on a rare metabolic disorder, where a replacement enzyme is delivered via mRNA to hepatocytes, seeking to correct enzyme deficiency and restore normal metabolic function.
Since its founding in 2013 and subsequent reorganization in 2020, GlobeStar Therapeutics has established operations in Miami, Florida, and maintains strategic partnerships in Europe and Asia to support global clinical development. The company’s integrated cGMP manufacturing capabilities enable streamlined scale-up from preclinical batches to commercial supply. GlobeStar’s pipeline strategy emphasizes indication selection where mRNA therapeutics can offer rapid development timelines and significant unmet medical need, positioning the firm to enter clinical trials efficiently and cost-effectively.
GlobeStar’s executive leadership team combines deep expertise in drug development, regulatory affairs, and manufacturing. The company is led by CEO Dr. Alexandra Reyes, a biopharmaceutical veteran with over two decades of experience in oncology and gene therapy. Chief Scientific Officer Dr. Marcus Lin brings a track record of translational research, while CFO Jane Matthison oversees financial and corporate strategy, having successfully guided multiple biotech firms through public offerings and strategic partnerships. Together, this leadership cadre is steering GlobeStar toward its goal of delivering next-generation mRNA therapeutics to patients worldwide.
AI Generated. May Contain Errors.
